Adenocarcinoma of the prostate is one of the commonest cancers in the world.
Due to a combination of earlier detection and better treatments, survival has increased dramatically. Prostate cancer itself is associated with lower bone density and increased fractures. This is compounded by the use of androgen deprivation therapy, which causes dramatic falls in circulating testosterone and estrogen, resulting in rapid falls in bone density, decreased muscle mass, and increased fracture rates. Bisphosphonates have been demonstrated to prevent and reverse this bone loss, but there are no anti-fracture data. Denosumab, a monoclonal antibody to RANKL, has recently been shown to increase bone density and reduce fracture rates. Prostate cancer also commonly metastasizes to bone where it can cause complications such as fracture and pain. Both zoledronic acid and denosumab have been demonstrated to reduce skeletal related events. Comparative studies would suggest that densosumab may have an advantage over zoledronic acid.
Written by:
Tuck SP, Hanusch B, Walker J, Datta HK. Are you the author?
Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Reference: Curr Osteoporos Rep. 2013 Jan 25. Epub ahead of print.
doi: 10.1007/s11914-012-0131-2
PubMed Abstract
PMID: 23355097
UroToday.com Prostate Cancer Section
